By IDSE News Staff
The FDA approved epoetin alfa-epbx (Retacrit, Pfizer) as a biosimilar to Epogen/Procrit (epoetin alfa (Epogen/Procrit, Amgen) to treat anemia caused by the use of zidovudine in patients with HIV infection. Epoetin alfa-epbx is approved as a biosimilar, not an interchangeable product.
Epoetin alfa-epbx also is approved for use on patients with chronic kidney disease, are taking chemotherapy, or before and after surgery to reduce the chance that red blood cell transfusions